• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

Trastuzumab deruxtecan superior to physician’s choice treatment in patients with metastatic HER2-positive breast cancer

byNeel MistryandTeddy Guo
June 13, 2023
in Chronic Disease, Oncology
Reading Time: 2 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. Progression-free survival was greater in the trastuzumab group compared to standard care (17.8 months vs. 6.9 months).

2. Drug-related interstitial lung disease was more common with patients receiving trastuzumab deruxtecan.

Evidence Rating Level: 1 (Excellent)

Study Rundown: A large proportion of breast cancers are characterized by overexpression of HER2 receptors. While first-line therapy for HER2-positive breast cancer includes monoclonal antibodies such as trastuzumab, a large proportion of patients continue to show disease progression. This randomized controlled trial aimed to compare the safety and efficacy of trastuzumab deruxtecan with physician’s choice treatment (either capecitabine plus trastuzumab or capecitabine plus lapatinib) in patients with HER2-positive metastatic breast cancer. The primary outcome was progression-free survival while key secondary outcomes included overall survival and objective response rates. According to study results, patients in the trastuzumab deruxtecan group demonstrated significantly improved progression-free survival than those in physician’s choice treatment group. This study was strengthened by a randomized design with individuals from multiple countries, thus adding to its generalizability.

Click to read the study in The Lancet

Relevant Reading: Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

RELATED REPORTS

Giredestrant plus everolimus improves progression-free survival in treatment-resistant breast cancer

Cognitive behaviour therapy may be superior to bright light therapy for insomnia in women with breast cancer undergoing chemotherapy

FDA approvedFor breast cancer: Etcamah (camizestrant), Sep 4, 2026→

In-depth [randomized-controlled trial]: Between Sept 6, 2018, and Dec 31, 2020, 816 patients were screened for eligibility across 227 clinical sites in North America, Europe, Asia, Australia, Brazil, Israel, and Turkey. Included were patients ≥ 18 years with HER2-positive unresectable or metastatic breast cancer, previous trastuzumab-emtansine therapy, an ECOG score of 0-1, and disease progression. Altogether, 608 patients (406 in trastuzumab and 202 in physician’s choice treatment) were included in the final analysis. The primary outcome of progression-free survival was significantly greater in the trastuzumab group (17.8 months) versus the physician’s choice treatment group (6.9 months; hazard ratio [HR] 0.36, 95% confidence interval [CI] 0.28-0.45, p<0.0001). The majority of adverse events were mild-to-moderate in nature and comparable between both groups (53% in trastuzumab vs. 44% in physician’s choice treatment). However, drug-related interstitial lung disease was more common with trastuzumab deruxtecan (10%) versus physician’s choice of therapy (1%). Overall, findings from this study suggest that trastuzumab may be both safe and effective for the treatment of metastatic breast cancer.

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: advanced breast cancerBreast CancercapecitabineHER2-positive breast cancerinterstitial lung diseaseLapatinibmetastatic breast cancertrastuzumabtrastuzumab deruxtecantrastuzumab emtansine
Previous Post

Deep neural networks trained to estimate reduced left ventricular ejection fraction from adult angiogram videos of left coronary artery

Next Post

#VisualAbstract: Cilta-cel or Standard Care in Lenalidomide Refractory Multiple Myeloma

RelatedReports

A middle-aged woman looks thoughtfully at an abstract representation of cells and a statin pill, symbolizing breast cancer and medication usage.
Oncology

Giredestrant plus everolimus improves progression-free survival in treatment-resistant breast cancer

October 5, 2026
Sleep disorders collage: an engraved pillow and rumpled sheet with a dark sleep mask, a paper crescent moon and a teal ribbon
Chronic Disease

Cognitive behaviour therapy may be superior to bright light therapy for insomnia in women with breast cancer undergoing chemotherapy

September 3, 2026
Breast cancer care collage: a calm woman in a turtleneck sweater beside a folded paper crane and a small white pill bottle
Chronic Disease

Tumour microenvironment factors may influence cancer progression and response to tamoxifen (Nolvadex) in patients with estrogen receptor-positive and human epidermal growth factor receptor 2 breast cancer

August 13, 2026
Sleep disorders collage: an engraved pillow and rumpled sheet with a dark sleep mask, a paper crescent moon and a teal ribbon
Weekly Rewinds

2 Minute Medicine Rewind August 10, 2026

August 10, 2026
Next Post
#VisualAbstract: Cilta-cel or Standard Care in Lenalidomide Refractory Multiple Myeloma

#VisualAbstract: Cilta-cel or Standard Care in Lenalidomide Refractory Multiple Myeloma

Pregnancy health collage: a pregnant woman in a sweater in profile, a fruit bowl, baby booties, city towers and trees

Elective induction of labour may improve outcomes and reduce labour-related complications

#VisualAbstract: Bariatric metabolic surgery more effective than medical therapy and lifestyle modifications for non-alcoholic steatohepatitis

#VisualAbstract: Bariatric metabolic surgery more effective than medical therapy and lifestyle modifications for non-alcoholic steatohepatitis

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Large genetic association study identifies additional Alzheimer disease risk loci and candidate pathways
  • Pelacarsen lowers lipoprotein(a) but does not reduce major cardiovascular events in patients with established cardiovascular disease
  • Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.